Contact
searchSearch
HMP Global

Biosimilars Topic Center

Featured Article

Conference Coverage
Real-World Strategies for Implementing Biosimilars
04/12/2023
Hannah Musick
Speakers at AMCP 2023 discussed the current landscape of biosimilars from a payer perspective as well as lessons learned from health system biosimilar adoption. 
Speakers at AMCP 2023 discussed the current landscape of biosimilars from a payer perspective as well as lessons learned from health system biosimilar adoption. 
Speakers at AMCP 2023 discussed...
04/12/2023
First Report Managed Care
From First Report Managed Care
Conference Insider
Addressing and Understanding Challenges Linked With Adopting Biosimilars Into Practice
12/08/2020
In a session at ASHP Midyear 2020, Osama Abdelghany, PharmD, MHA, BCOP Yale New Haven Hospital, and David L Crosby, PharmD, BCOP, BCPS, Dartmouth-Hitchcock Health, provide a variety of clinical, operational, and payer coverage considerations...
In a session at ASHP Midyear 2020, Osama Abdelghany, PharmD, MHA, BCOP Yale New Haven Hospital, and David L Crosby, PharmD, BCOP, BCPS, Dartmouth-Hitchcock Health, provide a variety of clinical, operational, and payer coverage considerations...
In a session at ASHP Midyear...
12/08/2020
Pharmacy Learning Network
Quiz
Identifying Pharmacist Knowledge of a Medication Drug Type
11/24/2020
Based on recent data, pharmacists are more well-informed about which medication type—with more than 80% demonstrating solid knowledge of their safety, efficacy, compatibility, and costs?
Based on recent data, pharmacists are more well-informed about which medication type—with more than 80% demonstrating solid knowledge of their safety, efficacy, compatibility, and costs?
Based on recent data,...
11/24/2020
Pharmacy Learning Network
News
Most Pharmacists Show Good Grasp of Biosimilar Medications, Study Finds
11/20/2020
“Pharmacists, being the drug experts, need to be well aware of the applied handling of biosimilar medicines,” researchers wrote. “They are an integral educator, trailblazer, and advocate of biosimilar integration across all clinical settings.”
“Pharmacists, being the drug experts, need to be well aware of the applied handling of biosimilar medicines,” researchers wrote. “They are an integral educator, trailblazer, and advocate of biosimilar integration across all clinical settings.”
“Pharmacists, being the drug...
11/20/2020
Pharmacy Learning Network
Newsfeed
Biosimilar Infliximab Appears Effective in Crohn`s Disease
12/11/2018
An infliximab biosimilar appears to be safe and effective in infliximab-naive patients with Crohn's disease, according to a recent study.
An infliximab biosimilar appears to be safe and effective in infliximab-naive patients with Crohn's disease, according to a recent study.
An infliximab biosimilar appears...
12/11/2018
Pharmacy Learning Network
News
Etanercept Biosimilar is Effective, Well-Tolerated for Rheumatoid Arthritis
02/16/2018
A recent study examined the efficacy of a biosimilar for treating patients with rheumatoid arthritis who respond inadequately to methotrexate
A recent study examined the efficacy of a biosimilar for treating patients with rheumatoid arthritis who respond inadequately to methotrexate
A recent study examined the...
02/16/2018
Pharmacy Learning Network
News
Biosimilar Infliximab Appears Safe, Effective in IBD Patients
12/15/2017
Researchers examined the effectiveness of switching to a biosimilar version of a drug in patients with IBD. 
Researchers examined the effectiveness of switching to a biosimilar version of a drug in patients with IBD. 
Researchers examined the...
12/15/2017
Pharmacy Learning Network
News
Pharmacist Role in Promoting Proper Biosimilar Usage
12/14/2017
Evelyn Hermes-Desantis, PharmD, BCPS, recently discussed the many factors involved in managing biosimilars in the hospital setting and the role pharmacists play in promoting their appropriate use in the context of safe patient care.
Evelyn Hermes-Desantis, PharmD, BCPS, recently discussed the many factors involved in managing biosimilars in the hospital setting and the role pharmacists play in promoting their appropriate use in the context of safe patient care.
Evelyn Hermes-Desantis, PharmD,...
12/14/2017
Pharmacy Learning Network
News
FDA Approves Another Biosimilar for RA Drug
12/14/2017
The FDA has approved a biosimilar for multiple autoimmune diseases. 
The FDA has approved a biosimilar for multiple autoimmune diseases. 
The FDA has approved a...
12/14/2017
Pharmacy Learning Network
News
FDA Approves First Biosimilar for Breast, Stomach Cancer
12/01/2017
The FDA has approved a biosimilar for two types of cancer.
The FDA has approved a biosimilar for two types of cancer.
The FDA has approved a...
12/01/2017
Pharmacy Learning Network
News
The Challenges of Bringing Biosimilars to Market
11/21/2017
Edward Li, Pharm D, MPH, BCOP, a professor in the Department of Pharmacy Practice at the University of New England College of Pharmacy, explains how industry experts can help bring biosimilars to the market faster.
Edward Li, Pharm D, MPH, BCOP, a professor in the Department of Pharmacy Practice at the University of New England College of Pharmacy, explains how industry experts can help bring biosimilars to the market faster.
Edward Li, Pharm D, MPH, BCOP, a...
11/21/2017
Pharmacy Learning Network

Newsfeed

News
Communication Needed to Improve Biosimilar Transition, Adherence
10/19/2017
Patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis who switched from an originator treatment to a biosimilar stopped taking the biosimilar medication within 6 months, a study showed. 
Patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis who switched from an originator treatment to a biosimilar stopped taking the biosimilar medication within 6 months, a study showed. 
Patients with rheumatoid...
10/19/2017
Pharmacy Learning Network
News
FDA Approves Amgen`s Cheaper Copy of Arthritis Drug Humira
09/23/2016
The FDA has approved a cheaper, biosimilar version of AbbVie's top-selling arthritis drug, Humira.
The FDA has approved a cheaper, biosimilar version of AbbVie's top-selling arthritis drug, Humira.
The FDA has approved a cheaper,...
09/23/2016
Pharmacy Learning Network
News
Novartis Biosimilar Takes Aim at Amgen`s Enbrel
10/23/2015
The FDA has accepted Novartis unit Sandoz's regulatory submission for approval of a biosimilar copy of Amgen's blockbuster anti-TNF drug Enbrel, the Swiss drugmaker said.
The FDA has accepted Novartis unit Sandoz's regulatory submission for approval of a biosimilar copy of Amgen's blockbuster anti-TNF drug Enbrel, the Swiss drugmaker said.
The FDA has accepted Novartis...
10/23/2015
Pharmacy Learning Network
News
FDA Proposes Adding Suffixes to Distinguish Biosimilar Drug Names
08/28/2015
The FDA proposed on Thursday identifying cheaper versions of biologic drugs with a suffix to distinguish them from their more expensive, branded counterparts.
The FDA proposed on Thursday identifying cheaper versions of biologic drugs with a suffix to distinguish them from their more expensive, branded counterparts.
The FDA proposed on Thursday...
08/28/2015
Pharmacy Learning Network
PharmLaw
Purdue Pharma Sentenced in Federal Opioid Case, Finalizing Fraud and Kickback Conspiracy Resolution
04/29/2026
Grace Taylor, MS, MA
Purdue Pharma’s federal sentencing finalizes a landmark opioid case involving fraud and kickback conspiracies, with lasting compliance implications for the pharmaceutical supply chain.
Purdue Pharma’s federal sentencing finalizes a landmark opioid case involving fraud and kickback conspiracies, with lasting compliance implications for the pharmaceutical supply chain.
Purdue Pharma’s federal...
04/29/2026
Pharmacy Learning Network
News
Memantine Hydrochloride Capsules Recalled for Failed Dissolution Specifications
04/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for memantine hydrochloride capsules due to failure to meet dissolution specifications.
The US Food and Drug Administration (FDA) has issued a Class II recall for memantine hydrochloride capsules due to failure to meet dissolution specifications.
The US Food and Drug...
04/23/2026
Pharmacy Learning Network
News
Semaglutide-Glycine-Cyanocobalamin Injectables Recalled for Lack of Sterility Assurance
04/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for semaglutide-glycine-cyanocobalamin injectable due to sterility assurance concerns, affecting 91 units.
The US Food and Drug Administration (FDA) has issued a Class II recall for semaglutide-glycine-cyanocobalamin injectable due to sterility assurance concerns, affecting 91 units.
The US Food and Drug...
04/23/2026
Pharmacy Learning Network
News
Essential Calming Skin Gel Recalled for Subpotent Drug
04/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class III recall for Essential Calming Skin Gel due to subpotent drug, affecting nearly 300 units.
The US Food and Drug Administration (FDA) has issued a Class III recall for Essential Calming Skin Gel due to subpotent drug, affecting nearly 300 units.
The US Food and Drug...
04/23/2026
Pharmacy Learning Network
PharmLaw
Executive Order Targets Accelerated Development and Access Pathways for Psychedelic Therapies in Mental Health
04/21/2026
Hannah Musick
A new executive order directs federal agencies to accelerate the development, review, and potential patient access to investigational psychedelic therapies for serious mental illness, signaling a shift in regulatory and research priorities...
A new executive order directs federal agencies to accelerate the development, review, and potential patient access to investigational psychedelic therapies for serious mental illness, signaling a shift in regulatory and research priorities...
A new executive order directs...
04/21/2026
Pharmacy Learning Network
News
Albuterol Sulfate Inhalation Solution Recalled for Illegible Labeling
04/16/2026
Hannah Musick
The US Food and Drug Administration (FDA) has issued a Class II recall for albuterol sulfate inhalation solution due to illegible labeling, affecting more than 146 000 unit-dose vials used in respiratory care.
The US Food and Drug Administration (FDA) has issued a Class II recall for albuterol sulfate inhalation solution due to illegible labeling, affecting more than 146 000 unit-dose vials used in respiratory care.
The US Food and Drug...
04/16/2026
Pharmacy Learning Network
News
Epinephrine Injection Recalled for Lack of Sterility Assurance
04/16/2026
Hannah Musick
The US Food and Drug Administration (FDA) has issued a Class II recall for epinephrine injection due to sterility assurance concerns, affecting more than 80 000 units used in emergency care settings.
The US Food and Drug Administration (FDA) has issued a Class II recall for epinephrine injection due to sterility assurance concerns, affecting more than 80 000 units used in emergency care settings.
The US Food and Drug...
04/16/2026
Pharmacy Learning Network
News
Cipla Cinacalcet Tablets Recalled for Nitrosamine Impurity Above Acceptable Limits
04/16/2026
Hannah Musick
The US Food and Drug Administration (FDA) has issued a Class II recall for multiple strengths of Cipla’s cinacalcet tablets due to nitrosamine impurity levels exceeding safety limits, raising concerns for long-term use in dialysis patients.
The US Food and Drug Administration (FDA) has issued a Class II recall for multiple strengths of Cipla’s cinacalcet tablets due to nitrosamine impurity levels exceeding safety limits, raising concerns for long-term use in dialysis patients.
The US Food and Drug...
04/16/2026
Pharmacy Learning Network
PharmLaw
CMS Proposes Sweeping Prior Authorization Reforms for Drugs, Expanding Transparency and Electronic Requirements
04/15/2026
Hannah Musick
The Centers for Medicare & Medicaid Services has proposed sweeping reforms to modernize prior authorization for drugs, introducing faster decision timelines, expanded electronic requirements, and new transparency measures that could...
The Centers for Medicare & Medicaid Services has proposed sweeping reforms to modernize prior authorization for drugs, introducing faster decision timelines, expanded electronic requirements, and new transparency measures that could...
The Centers for Medicare &...
04/15/2026
Pharmacy Learning Network
News
Xanax XR Tablets Recalled for Dissolution Failure
04/09/2026
Hannah Musick
The US Food and Drug Administration (FDA) has issued a Class II recall for Xanax XR tablets after testing revealed failed dissolution specifications, potentially affecting consistent drug release in patients treated for panic disorder.
The US Food and Drug Administration (FDA) has issued a Class II recall for Xanax XR tablets after testing revealed failed dissolution specifications, potentially affecting consistent drug release in patients treated for panic disorder.
The US Food and Drug...
04/09/2026
Pharmacy Learning Network

Insights

Interactive Features

Subscribe Today

Pharmacy Learning Network Newsletter

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use